First Wave BioPharma (FWBI) Peer Comparison

$2.07

$-- (--%)

As on 14-Jun-2024 09:30EDT

Market cap

$6 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1.9

Div. Yield

0 %

Edit

	First Wave BioPharma (FWBI)	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)
Market cap ($ Mln)	6	2,213	72
Revenue ($ Mln)	0	175	--
Net Profit ($ Mln)	-6.16	-190.42	-24.80
Net Margin (%)	-4,436.70	-106.30	--
RoE (%)	-15.18	-54.58	-81.55
Price to Earnings	--	--	--
Price-To-Book	1.87	7.00	2.11

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	First Wave BioPharma (FWBI)	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)
Operating Revenue	0.14	174.91	0.00
Cost of Revenue	0.07	6.93	0.00
Gross Profit	-0.03	159.62	--
Operating Expenses	20.91	374.53	25.24
Operating Profit (EBIT)	-20.93	-206.55	-25.24
Other Income	0.00	4.21	0.00
Profit before Tax	-21.02	-189.99	-24.80
Provision for Tax	-14.86	-0.03	0.45
Profit after Tax (Net Income)	-6.16	-190.42	-24.80
Minority Interest	0.00	0.00	0.00
Consolidated Profit	0.00	-48.56	-3.92

Liabilities ($ Mln)

	First Wave BioPharma (FWBI)	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)
Shareholder's Funds	77.86	316.05	23.15
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	7.10	21.45	0.00
Current Liabilities	6.17	83.43	6.74
Total Liabilities	6.88	473.57	38.04

Assets ($ Mln)

	First Wave BioPharma (FWBI)	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)
Non-Current Assets	83.64	70.99	0.00
Current Assets	7.49	349.94	29.90
Total Assets	6.88	473.57	38.04
Total Debt*	6.98	25.02	0.00
Net Current Assets	1.32	266.51	23.15

Cashflow ($ Mln)

	First Wave BioPharma (FWBI)	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)
Cash From Operating Activities	-12.38	-146.70	-20.48
Cash Flow from Investing Activities	--	--	--
Cash from Financing Activities	15.23	152.00	13.57
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	First Wave BioPharma (FWBI)	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)
ROCE (%)	-392.15	-52.15	-61.86
ROE (%)	-15.18	-54.58	-81.55
ROA (%)	-11.68	-33.49	-53.92
EBIT Margin (%)	-15,087.22	-118.35	--
Net Margin (%)	-4,436.70	-106.30	--
Cash Profit Margin (%)	-0.13	0.00	--

Growth Ratios

	First Wave BioPharma (FWBI)	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)
Revenue Growth (%)	--	26.51	--
EBIT Growth (%)	-184.52	-8.78	66.02
Net Profit Growth (%)	42.99	-7.87	13.70
EPS Growth (%)	--	2.78	39.58
Book Value Growth (%)	--	-31.49	-48.57

Valuation Ratios

	First Wave BioPharma (FWBI)	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)
Price / Earnings	--	-7.03	-1.04
Price / Book Value	--	3.91	0.71
Dividend Yield (%)	--	--	--
EV/EBITDA	0.18	-5.17	0.65
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	First Wave BioPharma (FWBI)	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)
Debt to Equity	0.08	0.00	0.00
Short term debt to equity ratio	0.01	0.01	0.00
Current Ratio	1.21	4.19	4.43
Quick Ratio	1.21	3.94	4.43
Interest Coverage	-262.77	-51.08	-13.08

Operating Efficiency Ratios

	First Wave BioPharma (FWBI)	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)
Debtors to sales (%)	0.00	18.69	--
Asset Turnover	0.00	0.31	0.00
Receivable days	--	60.80	--
Inventory Days	--	2,044.06	--
Payable days	7,949.79	2,206.38	--
Cash Conversion Cycle	--	-101.52	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly